Common Contracts
1 similar ' ' contracts
AMENDMENT #1 TO CLINICAL STUDY AGREEMENTAugust 9th, 2022
This Amendment (the "Amendment") to the Clinical Study Agreement, dated 21 November 2021 (the “Agreement”), for the clinical study (the “Study”) sponsored by Oppilan Pharma Limited, conducted in accordance with the protocol VTX002-201 “A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerative Colitis” and any amendments thereto (the “Protocol”), is made by and between:
